The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed primary glioblastoma multiforme.
K. F. Hofland
No relevant relationships to disclose
S. Hansen
Consultant or Advisory Role - Roche
M. Sorensen
Other Remuneration - Roche
H. P. Schultz
No relevant relationships to disclose
A. Muhic
No relevant relationships to disclose
S. Engelholm
No relevant relationships to disclose
A. Ask
No relevant relationships to disclose
C. Kristiansen
No relevant relationships to disclose
C. Thomsen
No relevant relationships to disclose
H. Skovgaard Poulsen
Consultant or Advisory Role - Roche
Honoraria - Roche
U. N. Lassen
No relevant relationships to disclose